Grand Pharmaceutical Group (FRA:MX6A) Retained Earnings: €1,165 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MX6A Grand Pharmaceutical Group Ltd FRA:MX6A
87 GF Score
Price €0.55
GF Value €0.62
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grand Pharmaceutical Group Retained Earnings?

Grand Pharmaceutical Group FRA:MX6A -2.68% 87 Retained Earnings is €1,165 Mil as of Dec. 2025. GuruFocus rates FRA:MX6A with a GF Score™ of 87/100 and a GF Value™ of €0.62 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Grand Pharmaceutical Group's retained earnings for the quarter that ended in Dec. 2025 was €1,165 Mil.

Grand Pharmaceutical Group's quarterly retained earnings declined from Dec. 2024 (€1,266 Mil) to Jun. 2025 (€1,167 Mil) and declined from Jun. 2025 (€1,167 Mil) to Dec. 2025 (€1,165 Mil).

Grand Pharmaceutical Group's annual retained earnings increased from Dec. 2023 (€1,041 Mil) to Dec. 2024 (€1,266 Mil) but then declined from Dec. 2024 (€1,266 Mil) to Dec. 2025 (€1,165 Mil).


Grand Pharmaceutical Group  (FRA:MX6A) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Grand Pharmaceutical Group Retained Earnings Historical Data

* Premium members only.

The historical data trend for Grand Pharmaceutical Group's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Pharmaceutical Group Retained Earnings Chart

Grand Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 914.70 1,041.28 1,265.92 1,164.57

Grand Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,041.28 1,130.13 1,265.92 1,166.58 1,164.57
FRA:MX6A
87GF Score
Grand Pharmaceutical Group Ltd FRA:MX6A
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grand Pharmaceutical Group Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €1,165 Mil mean?
Grand Pharmaceutical Group (FRA:MX6A) has a Retained Earnings of €1,165 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Grand Pharmaceutical Group and its competitors.
Is Grand Pharmaceutical Group's Retained Earnings too high?
Grand Pharmaceutical Group's current Retained Earnings is €1,165 Mil. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Retained Earnings compare to ZTS?
Grand Pharmaceutical Group's Retained Earnings of €1,165 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Grand Pharmaceutical Group and its competitors. Grand Pharmaceutical Group's current Retained Earnings is €1,165 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.62, compared to a current price of €0.55 — trading 12.1% below its estimated fair value. The current Retained Earnings is €1,165 Mil. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current Retained Earnings is €1,165 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?

Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued. The current stock price of €0.55 is trading 12.1% below its estimated GF Value™ of €0.62. GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.

Key valuation signals for FRA:MX6A:

  • Retained Earnings: €1,165 Mil
  • GF Value™: €0.62 vs. price of €0.55 (12.1% below fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grand Pharmaceutical Group Business Description

Other Exchanges 00512:Hong Kong
Address 99 Queen\'s Road Central, Units 3302, 33rd Floor, The Center, Hong Kong, HKG
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
87GF Score

Get the complete analysis for FRA:MX6A

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.55
Price
€0.62
GF Value